28 unknown. 28 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 28 | Unknown 28 |
| Phase 1 | 3 | Unknown 3 |
| Phase 3 | 1 | Unknown 1 |
Follow Fallopian Tube Diseases: new trials by email Literature Review of Fallopian Tube Diseases trials Research Report on Fallopian Tube Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi Fluzoparib, Fluzoparib+Apatinib - Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary | Phase 2 | Unknown | Guangxi Medical University | 80 | 2023-12-10 | 2023-12-07 |
| Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor Niraparib, Dostarlimab, Bevacizumab - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Unknown | University Health Network, Toronto | 40 | 2023-02-23 | 2024-01-17 |
| Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma Bevacizumab + modified FOLFIRINOX - Mucinous Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Unknown | Yonsei University | 37 | 2022-10-28 | 2022-12-29 |
| Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC SG001, Doxorubicin hydrochloride liposome injection - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 126 | 2021-09-01 | 2021-07-30 |
| A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer Gimatecan - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Unknown | Lee's Pharmaceutical Limited | 46 | 2021-07-01 | 2021-04-19 |
| Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients Pembrolizumab - Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 2 | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 100 | 2021-04-26 | 2021-12-20 |
| Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination Carboplatin, Paclitaxel, Bevacizumab - Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer | Phase 1 / Phase 2 | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 290 | 2021-03-17 | 2021-08-27 |
| Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer Niraparib, Bevacizumab - Ovarian Neoplasms, Fallopian Tube Neoplasms | Phase 2 | Unknown | Xiaoxiang Chen | 32 | 2020-11-06 | 2020-11-10 |
| Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients HIPEC, Carboplatin, Paclitaxel - Ovarian Cancer, Epithelial Ovarian Cancer | Phase 2 | Unknown | Andrea Jewell | 20 | 2017-12-15 | 2023-02-06 |
| Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas AVOVA-1, MC - Stage III Ovarian Carcinoma, Stage IV Ovarian Carcinoma | Phase 2 | Unknown | Aivita Biomedical, Inc. | 99 | 2017-11-18 | 2022-04-25 |
| Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer Vinorelbine - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Unknown | National University Hospital, Singapore | 36 | 2017-07-01 | 2018-03-29 |
| Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer DPX-Survivac, Cyclophosphamide, Epacadostat (INCB024360) - Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer | Phase 1 / Phase 2 | Unknown | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 85 | 2016-04-01 | 2021-06-18 |
| Total/Subtotal Colectomy in Ovarian Cancer Total or Subtotal Colectomy, Other Bowel Resection - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Unknown | Shanghai Gynecologic Oncology Group | 80 | 2015-07-01 | 2016-07-26 |
| p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer p53 gene, Cisplatin, Paclitaxel - Ovarian Epithelial Cancer, Fallopian Tube Cancer | Phase 2 | Unknown | Shenzhen SiBiono GeneTech Co.,Ltd | 100 | 2015-06-01 | 2015-05-06 |
| Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer carboplatin and paclitaxel followed by surgery - Ovarian Cancer, Fallopian Tube Carcinoma | Phase 2 | Unknown | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 129 | 2014-01-01 | 2022-12-30 |
| A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer carboplatin and paclitaxel - Fallopian Tube Cancer, Ovarian Cancer | Phase 2 | Unknown | Korean Gynecologic Oncology Group | 314 | 2010-03-01 | 2012-04-04 |
| Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer gemcitabine hydrochloride, liposome-encapsulated doxorubicin citrate, quality-of-life assessment - Fallopian Tube Cancer, Ovarian Cancer | Phase 2 | Unknown | Medical University Innsbruck | 154 | 2009-07-01 | 2013-08-26 |
| Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer therapeutic nutritional supplementation, standard follow-up care - Cervical Cancer, Endometrial Cancer | Phase 2 | Unknown | Centre Oscar Lambret | 120 | 2008-06-01 | 2009-07-29 |
| Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer carboplatin, gemcitabine hydrochloride, paclitaxel - Fallopian Tube Cancer, Ovarian Cancer | Phase 2 | Unknown | Warwick Medical School | 88 | 2007-10-01 | 2013-09-17 |
| Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy HIPEC: MMC 30mg @ T0, 10mg @ T45min, HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0, HIPEC: CDDP 75 mg/m2 @T0 - Ovarian Cancer, Peritoneal Cancer | Phase 2 | Unknown | Bay Area Gynecology Oncology | 200 | 2006-09-01 | 2019-04-16 |
Showing 20 of 28. Sign in to see all of them.
Fallopian Tube Neoplasms (28) · Ovarian Neoplasms (23) · Carcinoma, Ovarian Epithelial (18) · Endometrial Neoplasms (2) · Neoplasms (2) · Recurrence (2) · Uterine Cervical Neoplasms (2) · Adnexal Diseases (1) · Carcinoma (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Gastrointestinal Neoplasms (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Gonadal Disorders (1)
Female Urogenital Diseases (28) · Female Urogenital Diseases and Pregnancy Complications (28) · Genital Diseases (28) · Urogenital Diseases (28) · Adnexal Diseases (27) · Genital Diseases, Female (27) · Genital Neoplasms, Female (27) · Neoplasms by Site (27) · Urogenital Neoplasms (27) · Neoplasms (26) · Endocrine Gland Neoplasms (25) · Endocrine System Diseases (25) · Gonadal Disorders (25) · Ovarian Diseases (25)
Carboplatin (8) · Paclitaxel (8) · Bevacizumab (4) · Gemcitabine (3) · Hyperthermic Intraperitoneal Chemotherapy (2) · niraparib (2) · oregovomab (2) · 1-dodecylpyridoxal (1) · Cisplatin (1) · Cyclophosphamide (1) · Diathermy (1) · Docetaxel (1) · Filgrastim (1) · Ganciclovir (1) · Genes, p53 (1)
AltaRex (2) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (2) · Herbert Irving Comprehensive Cancer Center (2) · Aivita Biomedical, Inc. (1) · Andrea Jewell (1) · Bay Area Gynecology Oncology (1) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Centre Oscar Lambret (1) · Guangxi Medical University (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · ImmunoVaccine Technologies, Inc. (IMV Inc.) (1) · John Stoddard Cancer Center at Iowa Methodist Medical Center (1) · Korean Gynecologic Oncology Group (1) · Lee's Pharmaceutical Limited (1) · Ludwig-Maximilians - University of Munich (1)
United States (10) · Canada (4) · China (4) · Italy (3) · South Korea (2) · United Kingdom (2) · Australia (1) · Austria (1) · France (1) · Germany (1) · Hungary (1) · Netherlands (1) · Singapore (1)
Amy D. Tiersten, MD (2) · Alain Zeimet (1) · Andrea Jewell, MD (1) · Charles Joseph Link, MD (1) · Christopher Poole, MD (1) · Claudio Zamagni, MD (1) · David Tan (1) · Domenica Lorusso, Prof. (1) · Gordon J.S. Rustin, MD (1) · Harald Sommer, MD (1) · Isabelle Rodrigues-Lebrun (1) · James Lilja, MD (1) · Jonathan S. Berek, MD (1) · Maurie Markman, MD (1) · Michael A. Bookman, MD (1)
PMID 10623700, PMID 10628376, PMID 10793106, PMID 11309294, PMID 11331762, PMID 11459964, PMID 11533692, PMID 12205100, PMID 12217790, PMID 12241653, PMID 12460789, PMID 14701743, PMID 15327776, PMID 15367671, PMID 15665856, PMID 1581961, PMID 15829966, PMID 15829967, PMID 15905196, PMID 16239238, PMID 16357170, PMID 16394300, PMID 16912188, PMID 16946210, PMID 17714938, PMID 18024865, PMID 18268546, PMID 18955455, PMID 19049966, PMID 19553641, PMID 19779458, PMID 19819917, PMID 20551068, PMID 20606085, PMID 20609467, PMID 20609468, PMID 21720365, PMID 21862407, PMID 22203755, PMID 22204724, PMID 22204725, PMID 22237781, PMID 22452356, PMID 22576213, PMID 22711857, PMID 22912389, PMID 23047548, PMID 23118055, PMID 23512992, PMID 23810467